
To evaluate the performance of the 2017 EULAR/ACR classification criteria in a cohort of anti‐MDA5 associated IIM patients. Almost 30% of patients with clinical anti‐MDA5 associated IIM could not be classified by the EULAR/ACR criteria. Modification of the existing criteria incorporating anti‐MDA5 antibody or development of a new specific set of criteria for “anti‐MDA5 syndrome” are suggested.
Like
Save
Share